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Abstract Biologics targeting TNF have brought about a
paradigm shift in the treatment of rheumatoid arthritis (RA)
and inﬂiximab, anti-TNF-a chimeric monoclonal antibody,
was marketed in 2003 in Japan. We previously reported on
the RECONFIRM study, a retrospective clinical study on
the efﬁcacy of inﬂiximab therapy in a RA management
group in Japan, where we evaluated the clinical response
after 22 weeks of the therapy in 258 patients. The study
reported here was aimed at reconﬁrming the clinical efﬁ-
cacy of the inﬂiximab therapy and demographic factors
related to the efﬁcacy over a 54-week study period in
410 RA patients in the same study group. Inﬂiximab
was infused according to the domestically approved
method, and the clinical response was evaluated following
54 weeks of inﬂiximab therapy using the European League
Against Rheumatism (EULAR) response criteria. Disease
activity was assessed by DAS28-CRP (Disease Activity
Score including a 28-joint count/C-reactive protein). Inf-
liximab was discontinued in 24.4% of the 410 patients at
54 weeks and 9.3% and 8.1% discontinued the therapy due
to adverse events and inefﬁciency, respectively. Average
DAS28-CRP decreased from 5.5 at week 0 to 3.1 at week
54 after the therapy. Patients in remission and those
showing low-, moderate-, and high-disease activity chan-
ged from 0.0, 1.0, 9.0 and 90.0%, respectively, at the start
of the study to 27.6, 11.7, 34.4 and 26.3%, respectively,
at week 54. Younger age, RF-negativity and low scores
of DAS28-CRP showed signiﬁcant correlations with
remission at week 54. EULAR response criteria—good,
moderate, and no response to inﬂiximab—were 37.0, 41.7
and 21.2%, respectively. In conclusion, we reconﬁrmed the
clinical efﬁcacy of inﬂiximab and demographic factors
related to the efﬁcacy over a 54-week study period in 410
Japanese patients with RA using DAS28-CRP and EULAR
response criteria.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inﬂam-
matory disease that causes signiﬁcant morbidity and
mortality. RA patients should be started with DMARDs as
early as possible, and among multiple DMARDs metho-
trexate (MTX) is considered the anchor drug and should be
used ﬁrst of all. However, even the use of MTX often fails
to control disease activity and to prevent structural damage,
and so more effective treatment strategies are needed.
TNF-a plays a pivotal role in the pathological processes of
RA through the accumulation of inﬂammatory cells and the
self-perpetuation of inﬂammation, leading to cartilage and
bone destruction. The combinational use of biologics tar-
geting TNF-a and MTX has revolutionized the treatment
of RA, producing signiﬁcant improvements in clinical,
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viously observed [1–5].
Inﬂiximab, anti-TNF-a chimeric monoclonal antibody,
has been marketed since July 2003 in Japan and currently
provides high efﬁcacy and potential adverse events.
Although global evidence of the efﬁcacy and safety of
inﬂiximab has accumulated, including the ATTRACT
study, ASPIRE study and many others [6–10], there is no
well-established ﬁrm evidence of the efﬁcacy of this agent
in Japan. Only the RECONFIRM study, a retrospective
clinical study on the notable efﬁcacy and related factors of
inﬂiximab therapy in a RA management group in Japan,
has reported clinical evidence on its efﬁcacy and safety;
this study was performed in several major rheumatology
centers in Japan [11]. However, the RECONFIRM study
evaluated the clinical response following only 22 weeks of
inﬂiximab therapy in 258 patients.
In this RECONFIRM-2 study, we assessed the clinical
efﬁcacy and safety of inﬂiximab and MTX over a 54-week
study period when used in 410 RA patients in the same
group, in order to reconﬁrm not only its clinical efﬁcacy
but also demographic factors related to the efﬁcacy.
Patients and methods
Data and information on RA patients that fulﬁlled the diag-
nostic criteria of the American College of Rheumatology
(ACR) were collected from three major rheumatology
centers in Japan, including the First Department of Internal
Medicine, School of Medicine, University of Occupational
and Environmental Health Japan, Kitakyushu; the Division
of Rheumatology and Clinical Immunology, Department of
Internal Medicine, Saitama Medical Center, Saitama
Medical University, Saitama; and the Institute of Rheu-
matology, Tokyo Women’s Medical University. All
patients that received inﬂiximab treatment in each institu-
tion by December 2005 were registered with this
retrospective study. Demographic data, including disease
duration and concomitant therapy, were collected from
medical charts. The following parameters were evaluated
before and at 54 weeks after the initial inﬂiximab infusion:
tender joint count (TJC) 28, swollen joint count (SJC) 28,
patient’s assessment of pain on a visual analog scale
(patient’s pain VAS), patient’s global assessment of dis-
ease activity (patient’s global VAS), physician’s global
assessment of disease activity (physician’s global VAS),
and C-reactive protein (CRP).
Inﬂiximab therapy
Inﬂiximab was infused to patients at zero, two, and six
weeks and thereafter every eight weeks at a dose of 3 mg/
kg according to the drug labeling and the guidelines of the
Inﬂiximab Study Group in the Ministry of Health, Welfare
and Labor in Japan [12]. Concomitant use of MTX was
instituted in all cases, although the dose of MTX was
determined by each attending physician.
Therapeutic response
Disease activity was assessed by Disease Activity Score,
including a 28-joint count (DAS28)-CRP that was calcu-
lated according to the authorized formula (http://www.
das-score.nl/). The value of DAS28-CRP is reported to be
less than the original DAS28 using the erythrocyte sedi-
mentation rate (ESR), and we used a thresholdof 4.1 instead
of the original 5.1 as the cut-off for high activity and 2.7
instead of 3.2 as the cut-off for low activity. Thus, we
deﬁned a value of DAS28-CRP[4.1 as high activity, 2.7–
4.1 as moderate activity, \2.7 as low activity, with \2.3
being deﬁned as remission [9]. The response to inﬂiximab
therapy at 22 weeks was evaluated by the European League
Against Arthritis (EULAR) response criteria using 4.1 and
2.7 as the thresholds for the high and low disease activities,
respectively [13]. Secondary insufﬁciency to inﬂiximab was
deﬁned as patients with good or moderate EULAR response
at week 22, and whose DAS28 increased to[0.6 or[1.2
from week 22 to 54.
Discontinued subjects
The continuation rate of inﬂiximab therapy was calculated
by all causes of discontinuation. Cumulative hazards and
associated factors were analyzed in relation to three types of
discontinuation: adverse events, inefﬁcacy, and remission.
Statistical analysis
Baseline characteristics of patients are summarized in
Table 1 using the mean, standard deviation, median, 25%,
and 75% values for continuous variables. The continuation
rate of inﬂiximab therapy was calculated using the Kaplan–
Meier estimator in pooled samples of three institutes. The
discontinuation-cause speciﬁc hazards were estimated
using the Nelson–Aalen estimator. Next, risk factors for the
discontinuations were evaluated using the stratiﬁed pro-
portional hazards model in order to adjust for differences
among institutions. The clinical efﬁcacies of inﬂiximab
were evaluated using a multivariate logistic regression to
adjust for institutional effects. In this analysis, the last
observed DAS28-CRP values were used for discontinued
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123patients. All multivariate analyses were conducted using
the variables gender, age, duration of disease, positive/
negative rheumatoid factor (RF), concomitant MTX dose,
concomitant prednisolone (PSL) dose, and DAS28-CRP at
baseline. All reported P-values are two-sided and are not
adjusted for multiple testing. The signiﬁcance level was set
at a P value of\0.05.
Results
Baseline demographic and clinical characteristics
The baseline demographic and clinical characteristics of
410 patients receiving inﬂiximab therapy are summarized
in Table 1. Patients had active disease at baseline as evi-
denced by high mean counts of tender and swollen joints,
CRP levels, and the DAS28. Age, sex, and disease duration
were similar among these three institutes, while the %user
and dose of MTX or PSL were divergent and the disease
activities as assessed by TJC, SJC, GH, and DAS28 was
also different.
Continuation of inﬂiximab therapy
Inﬂiximab was discontinued in 100 cases (24.4%) among
410 patients during a 54-week period and the survival rate
for inﬂiximab use was comparable among three institutes
by week 54 after the treatment according to Kaplan–
Meier analysis (Fig. 1a). Cumulative hazards of the dis-
continuation during the 54-week inﬂiximab therapy were
different among the causes of discontinuation; discontin-
uation due to adverse events, inefﬁciency, remission and
other causes (such as change of hospitals/clinics and
economic reasons), were 0.093, 0.081, 0.007 and 0.063,
respectively (Fig. 1b). Although the cause of the discon-
tinuation was similar among three institutes, adverse
events were higher in Center 1 than in the other two
institutes, and remission and other causes including eco-
nomic problems of the patient were greater in Center 3
than in the other two (data not shown). In 100 patients
who terminated inﬂiximab treatment, stratiﬁed Cox
regression was performed to analyze factors associated
with the discontinuation of the infusion. Male, older age
and RF-negativity were signiﬁcantly associated with the
discontinuation of inﬂiximab due to adverse reactions,
whereas there was no signiﬁcant factor responsible for the
discontinuation due to maintained remission or a lack of
efﬁcacy (Table 2).
Table 1 Baseline characteristics of patients in three institutions of
rheumatology in Japan
Mean SD Min 25% Median 75% Max
Female (%) 87.6 – – – – – –
Age 53.1 12.7 19 46 55 62 80
Duration 9.4 8.8 0 3 6.6 13 54
Stage 3.0 1.0 1 2 3 4 4
Class 2.2 0.5 1 2 2 2 4
RF positive (%) 87.6 – – – – – –
RF (titer) 213 331 1 39 96 241 2980
MTX dose 7.8 2.0 0 6 8 8 20
PSL dose 3.8 3.7 0 0 4 5 22.5
CRP 3.3 2.8 0 1.18 2.7 4.7 13.7
TJC28 10.5 7.3 0 5 9 15 28
SJC28 10.6 6.1 0 6 10 14 28
GH 63.1 21.9 0 49.3 66 80 100
DAS28-CRP 5.5 1.1 1.9 4.8 5.6 6.3 8.0
MTX methotrexate, PSL prednisolone, RF rheumatoid factor, CRP C-
reactive protein, GH general health, TJC tender joint count, SJC
swollen joint count, DAS disease activity score
Fig. 1 Continuation of the
inﬂiximab therapy in RA
patients for 54 weeks.
a Survival rate of RA patients
treated with inﬂiximab
(n = 410, total and three
institutes) during the 54-week
therapy. b Cumulative hazards
of the discontinuation of
inﬂiximab therapy by week 54
of the treatment
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The average DAS28-CRP before starting inﬂiximab was
5.5 ± 1.1, and this decreased to 3.4 ± 1.2, 3.2 ± 1.4,
3.1 ± 1.3 at weeks 2, 22 and 54, respectively, after the
inﬂiximab therapy (Fig. 2). Disease characteristics at
baseline and after 2, 22 and 54 weeks of the inﬂilximab
therapy were as follows: tender joints count (10.5, 4.2, 3.2
and 2.9), swollen joints count (10.6, 4.2, 2.7 and 2.3), GH
(63, 34, 33 and 33 mm), and CRP (3.3, 1.0, 1.5 and 1.1 mg/
dl) (Fig. 3). Before starting inﬂiximab, the proportions of
patients showing low, moderate, and high disease activity
were 1.0, 9.0 and 90.0%, respectively. At week 22, patients
in remission (deﬁned as DAS28-CRP \2.3) and those
showing low (\2.7), moderate (2.7–4.1), and high disease
activity ([4.1) had changed to 27.8, 12.0, 32.4 and 27.8%,
respectively, and at week 54 patients in remission and
those showing low, moderate, and high disease activity
were 27.6, 11.7, 34.4 and 26.3%, respectively (Fig. 4).
Thus, approximately 27–28% of the patients satisﬁed the
remission criteria at week 22 and still remained at week 54
after the inﬂiximab therapy. Also, when the responses were
evaluated by the EULAR response criteria, the proportions
for good, moderate, and no response to inﬂiximab as
measured by DAS28-CRP were 37.3, 43.7 and 19.0%,
respectively, at week 22 and 37.0, 41.7 and 21.2%,
respectively, at week 54 (Fig. 5).
Demographic factors related to the clinical efﬁcacy
of inﬂiximab therapy
In order to clarify demographic factors related to the
clinical efﬁcacy of inﬂiximab therapy, we performed a
multivariate analysis adjust for institutional differences.
Younger age, RF-negativity and lower levels of DAS28-
CRP were signiﬁcantly associated with the clinical remis-
sion induced by inﬂiximab therapy at week 54, whereas
gender, duration of the disease, dose of MTX and dose
of PSL did not show a signiﬁcant association (Table 3).
On the other hand, most of the demographic factors, except
for older age, did not affect secondary insufﬁciency from
week 22 to 54 after the inﬂiximab therapy according to the
logistic regression analysis (Table 4).
Discussion
The RECONFIRM-2 study was designed to fully evaluate
the effect of inﬂiximab used in combination with MTX on
the clinical results during a 54-week study period in
DMARD-resistant RA patients of a RA management
group in Japan. The safety proﬁle of inﬂiximab therapy
for a total of 5,000 cases was investigated in Japan using
an all-case registered post-marketing surveillance system,
and the entire proﬁle of adverse events related to inﬂix-
imab therapy was clearly identiﬁed [14]. The assessment
of efﬁcacy, however, was based only on the physician’s
general evaluation and not on quantitative measures such
as EULAR criteria. In this report, therefore, efﬁcacy data
Table 2 Results from a Cox regression analysis performed to examine the factors related to the discontinuation of inﬂiximab therapy
Variable AE (n = 38) Inefﬁcacy (n = 33) Remission (n = 3)
Coef. HR CL CU P Coef. HR CL CU P Coef. HR CL CU P
Age 0.037 1.038 1.006 1.070 0.020 -0.014 0.987 0.957 1.017 0.38 -0.021 0.980 0.888 1.081 0.68
Gender -0.940 0.391 0.177 0.863 0.020 0.160 1.173 0.352 3.910 0.79 – – – – –
RA duration 0.018 1.018 0.983 1.054 0.320 0.005 1.005 0.964 1.046 0.83 -0.114 0.893 0.622 1.280 0.54
RF (±) -0.949 0.387 0.171 0.878 0.023 1.545 4.686 0.635 34.573 0.13 -1.150 0.317 0.023 4.291 0.39
MTX dose 0.096 1.101 0.920 1.318 0.290 -0.142 0.867 0.709 1.060 0.16 0.339 1.403 0.799 2.465 0.24
PSL dose -0.066 0.936 0.848 1.033 0.190 0.003 1.003 0.908 1.109 0.95 -0.636 0.529 0.187 1.500 0.23
DAS (0 week) 0.205 1.227 0.890 1.692 0.210 0.113 1.120 0.815 1.537 0.49 -0.474 0.623 0.164 2.367 0.49
Coef. coefﬁcient, HR hazard ratio, CL 95% conﬁdence lower limit of HR, CU 95% conﬁdence upper limit of HR
Fig. 2 Longitudinal analysis of DAS28 values during the 54-week
study of patients using inﬂiximab. Line in the box represents the
median and the upper and lower ends of the box show the 25th and
75th percentiles of the population
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were intensively assessed. The average DAS28-CRP
before starting inﬂiximab was 5.5, it decreased to 3.2 at
week 22 and it remained steady at 3.1 by week 54 after
the inﬂiximab therapy. At week 22 after the therapy,
about 28% and 40% of patients satisﬁed the remission and
low disease activity criteria, respectively, and these
effects remained (28 and 39%, respectively) by week 54.
Also, about 37% of the patients exhibited good response
according to EULAR criteria continuously from week 22
to 54. These results reconﬁrmed that the clinical efﬁcacy
of inﬂiximab at week 22 was maintained until week 54 in
most of the patients treated with inﬂiximab. Thus,
appropriate treatment with inﬂiximab and MTX in this
study group could minimize secondary insufﬁciency of
the therapy for at least one year.
On the other hand, the discontinuation of inﬂiximab was
observed in approximately 24% of the patients during the
54-week period. This rate of discontinuation of the therapy
was comparable to that obtained in other countries: 26.7%
Fig. 3 Longitudinal analysis of
a SJC28, b TJC28, c CRP, and
d GH values during the 54-week
study of patients using
inﬂiximab. Line in the box
represents the median, and the
upper and lower ends of the box
show the 25th and 75th
percentiles of the population
Fig. 4 Changes in DAS28 values during the 54-week study of
patients using inﬂiximab. The ratios of patients who demonstrated
high disease activity (deﬁned as DAS28-CRP [4.1), moderate
activity (2.7–4.1), low activity (\2.7) and remission (\2.3) at each
observation point during the 54-week study are shown
Fig. 5 The response to inﬂiximab therapy during the 54-week study.
The ratios of patients whose responses were evaluated by the
European League Against Arthritis (EULAR) response criteria are
shown
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123in the Anti-Tumor Necrosis Factor Trial in Rheumatoid
Arthritis with Concomitant Therapy (ATTRACT) interna-
tional study carried out in the USA and the EU, 34.6% in a
German domestic study and 26% in a French group study
during the ﬁrst one-year period [7, 15, 16]. Cumulative
hazards differed among causes of discontinuation; discon-
tinuations due to adverse events, inefﬁciency, remission
and other causes (including changes of hospital/clinic and
economic problems) were 0.093, 0.081, 0.007 and 0.063,
respectively. Male gender, older age and RF-negativity
were signiﬁcantly correlated with discontinuation of
inﬂiximab due to adverse reactions, including infusion
reactions (N = 7), toxicoderma (4), bacterial pneumonia
(3), pneumocystis jirovecii pneumonia (3), but more than
two-thirds of the withdrawals due to adverse events were
observed within the ﬁrst 14 weeks after the therapy.
In this study, to clarify how predisposing factors from
the demographic characteristics of RA patients were rela-
ted to the clinical efﬁcacy of inﬂiximab therapy, a
multivariate analysis using a logistic regression was per-
formed. In this study, multiple variables including sex, age,
duration of disease, stage, class, positive/negative RF,
concomitant MTX dose, concomitant PSL dose, and initial
levels of CRP, TJC, SJC and GH were assessed. It is worth
noting that, among multiple variables, younger age, RF-
negativity and lower levels of DAS28-CRP at the baseline
were signiﬁcantly correlated with the clinical remission
induced by inﬂiximab therapy at week 54. These results
imply that the timely use of MTX and inﬂiximab can be
strongly recommended for younger RA patients that show
RF-negativity in order to efﬁciently achieve clinical
remission. On the other hand, male gender, older age and
Table 3 Results from the logistic regression analysis used to examine the factors related to clinical remission at weeks 22 and 54 induced by
inﬂiximab therapy
Variables Week 22 (n = 113) Week 54 (n = 112)
Coef. OR SE CL CU P Coef. OR SE CL CU P
Intercept 1.530 4.617 1.034 0.608 35.067 0.139 1.770 5.868 1.010 0.811 42.445 0.080
Center 2 vs. Center 1 0.174 1.190 0.359 0.588 2.405 0.629 0.564 1.758 0.350 0.886 3.488 0.107
Center 3 vs. Center 1 1.072 2.922 0.324 1.549 5.510 0.001 0.989 2.689 0.325 1.423 5.082 0.002
Age -0.014 0.986 0.010 0.967 1.006 0.168 -0.024 0.976 0.010 0.957 0.995 0.014
Gender 0.563 1.755 0.392 0.813 3.787 0.152 0.154 1.166 0.370 0.565 2.409 0.677
RA duration -0.007 0.993 0.015 0.964 1.023 0.640 0.010 1.010 0.014 0.982 1.039 0.491
RF (±) -0.413 0.662 0.339 0.340 1.287 0.224 -0.742 0.476 0.329 0.250 0.908 0.024
MTX dose 0.042 1.043 0.068 0.913 1.193 0.535 0.005 1.005 0.066 0.884 1.143 0.936
PSL dose -0.063 0.939 0.035 0.876 1.005 0.070 -0.058 0.944 0.034 0.882 1.009 0.092
DAS28-CRP -0.464 0.629 0.116 0.501 0.789 0.000 -0.276 0.759 0.112 0.609 0.945 0.014
Coef. coefﬁcient HR, OR odds ratio, SE standard error, CL 95% conﬁdence lower limit of OR, CU 95% conﬁdence upper limit of OR
Table 4 Results from the logistic regression analysis used to examine the factors related to the secondary inefﬁciency from week 22 to 54 during
inﬂiximab therapy
Variables Week 54–22[0.6 (n = 85) Week 54–22[1.2 (n = 47)
Coef. OR SE CL CU P Coef. OR SE CL CU P
(Intercept) -1.461 0.232 1.079 0.028 1.923 0.176 -4.331 0.013 1.439 0.001 0.221 0.003
Center 2 vs. Center 1 -0.008 0.992 0.350 0.499 1.970 0.981 0.074 1.077 0.440 0.455 2.549 0.866
Center 3 vs. Center 1 0.071 1.073 0.333 0.559 2.060 0.831 0.054 1.056 0.426 0.458 2.433 0.899
Age 0.019 1.019 0.011 0.998 1.042 0.079 0.032 1.032 0.014 1.004 1.062 0.028
Gender -0.283 0.753 0.358 0.373 1.520 0.429 0.250 1.284 0.511 0.471 3.500 0.625
RA duration -0.029 0.972 0.017 0.941 1.004 0.083 -0.020 0.980 0.020 0.942 1.019 0.313
RF (±) -0.233 0.792 0.366 0.387 1.622 0.524 0.164 1.178 0.512 0.432 3.212 0.749
MTX dose -0.001 0.999 0.069 0.873 1.144 0.990 0.039 1.040 0.086 0.879 1.230 0.649
PSL dose -0.015 0.985 0.036 0.918 1.057 0.682 0.019 1.019 0.045 0.934 1.112 0.676
DAS28-CRP (0 week) -0.033 0.967 0.118 0.767 1.219 0.779 -0.011 0.989 0.148 0.739 1.323 0.941
Coef. coefﬁcient HR, OR odds ratio, SE standard error, CL 95% conﬁdence lower limit of OR, CU 95% conﬁdence upper limit of OR
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123RF-negativity were signiﬁcantly correlated with discon-
tinuation of inﬂiximab due to adverse reactions, whereas
there was no signiﬁcant factor responsible for discontinu-
ation as a result of inefﬁcacy, and only older age affected
secondary insufﬁciency from week 22 to 54 after the inf-
liximab therapy. Although it is intriguing that male gender
predisposes for discontinuation as a result of adverse
events, these results provide the ﬁrst information that can
be used to facilitate the more efﬁcacious use of inﬂiximab
and MTX in the daily practice of rheumatologists.
Taken together, this REOCNFIRM-2 study reconﬁrms
the clinical efﬁcacy of treatment with inﬂiximab and MTX
in Japanese RA patients using the DAS28-CRP and EU-
LAR response criteria. Among 410 patients with active
RA, approximately 28% and 39% of the patients satisﬁed
the remission and low disease activity criteria, and good
response according to the EULAR criteria was achieved in
37% of the patients treated with inﬂiximab plus MTX
during the 54-week study period. The clinical efﬁcacy of
inﬂiximab was maintained from week 22 to 54 after the
treatment, and secondary insufﬁciency after week 22 was
marginal after the appropriate treatment in this study
group. Several demographic factors, including male gen-
der, RF-negativity and lower scores of DAS28-CRP, were
signiﬁcant predisposing factors for remission. The prom-
ising effectiveness of inﬂiximab at improving measures of
disease activity in RA patients has led to this therapy
becoming one of the key advances in the management of
RA. Thus, this study is important because it provides
obvious and invaluable evidence concerning the efﬁcacy of
the combinational use of inﬂiximab and MTX, and can
guide the real clinical use of inﬂiximab in the future.
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